title: Phase II study of 4-demethoxydaunorubicin in previously untreated extensive disease non-small cell lung cancer.
abstract: Fifteen patients with previously untreated extensive non-small cell lung cancer (E-NSCLC) were treated with oral 4-demethoxydaunorubicin (4-DMDR) at the dose of 10 mg/m2/day x 5 days every 3 weeks with routine administration of antiemetic drugs. They received a median of two courses of treatment with the cumulative dose range from 50-712.5 mg/m2. One patient achieved partial remission with a duration of 14 weeks. Two patients had minor responses with durations of 14 and 24 weeks. Stable disease occurred in three patients (21, 22, and 27 weeks). Median survival was 33 weeks (range 3-73+ weeks). Toxicities were tolerable. Neutropenia (less than 1,000 mm3) occurred in only 16% of all treatment courses. Three patients developed correctable arrhythmias (two with atrial fibrillation and one with accelerated junctional rhythm). The cause of arrhythmia was unclear. No clinical evidence of congestive heart failure or decreased cardiac ejection fraction was observed. Nausea and vomiting were common but tolerable. Alopecia and mucositis were uncommon. Clinical pharmacokinetic studies were done in nine patients. However, plasma 4-DMDR levels were below the limit of detection (3 ng/ml). Because 4-DMDR has shown some activity in previously untreated E-NSCLC and the toxicities at this dose schedule are mild, we suggest that further studies of this drug at a higher dose in this schedule are indicated.
authors.affiliation: Section of Head and Neck, University of Texas M.D. Anderson Cancer Center, Houston.
authors.forename: T
authors.initials: T
authors.lastname: Umsawasdi
authors.forename: T B
authors.initials: TB
authors.lastname: Felder
authors.forename: D
authors.initials: D
authors.lastname: Jeffries
authors.forename: R A
authors.initials: RA
authors.lastname: Newman
mesh_terms: D000328:Adult; D000368:Aged; D001682:Biological Availability; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000493:pharmacokinetics / Q000627:therapeutic use* / Q000633:toxicity; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
chemical_list: D015255:Idarubicin